ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
accruals factor · long-only model fund

Foundry Healthcare dNOA Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FDNHHYPOTHETICAL MODEL
Since ’99
+80%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Jun 2022
placeholder
Full Sharpe
0.21
Ann. Return (LS)
4.1%
Ann. Volatility
19.8%
Max Drawdown
-48.6%
Test Sharpe ’19–26
0.10
Test FF5 α (ann.)
3.6%
vs Fama-French 5
Test FF5 α t-stat
0.52
not significant
Monthly turnover
18%
of the long leg, per rebalance
Cumulative return (LS)
80%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.65
what this fund holds
Long leg ann. return
12.6%
buyable, long-only
Long-short Sharpe
0.21
requires shorting
Bottom bucket ann. return
8.5%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
10.94%
2CNC
CENTENE CORPHealthcare$32.81B
9.07%
3DXCM
DEXCOM INCHealthcare$29.58B
8.18%
4MRNA
MODERNA INCHealthcare$24.53B
6.78%
5UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
6.29%
6BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
4.41%
7MEDP
MEDPACE HOLDINGS INCHealthcare$15.36B
4.25%
8BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
3.79%
9BMRN
BIOMARIN PHARMACEUTICAL INCHealthcare$11.52B
3.18%
10CYTK
CYTOKINETICS INCHealthcare$9.98B
2.76%
11PTGX
PROTAGONIST THERAPEUTICS INCHealthcare$9.06B
2.50%
12OSCR
OSCAR HEALTH INCHealthcare$8.77B
2.43%
13IBRX
IMMUNITYBIO INCHealthcare$8.04B
2.22%
14MIRM
MIRUM PHARMACEUTICALS INCHealthcare$7.25B
2.00%
15SRRK
SCHOLAR ROCK HOLDING CORPHealthcare$6.33B
1.75%
16DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
1.34%
17VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
1.19%
18ALHC
ALIGNMENT HEALTHCARE INCHealthcare$4.26B
1.18%
19DOCS
DOXIMITY INCHealthcare$3.94B
1.09%
20RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
1.05%
21DNLI
DENALI THERAPEUTICS INCHealthcare$3.70B
1.02%
22ACHC
ACADIA HEALTHCARE COMPANY INCHealthcare$3.17B
0.88%
23IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
0.87%
24XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
0.78%
25CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
0.77%
26VERA
VERA THERAPEUTICS INCHealthcare$2.76B
0.76%
27KOD
KODIAK SCIENCES INCHealthcare$2.67B
0.74%
28IMNM
IMMUNOME INCHealthcare$2.53B
0.70%
29BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.65%
30AGIO
AGIOS PHARMACEUTICALS INCHealthcare$2.36B
0.65%
31BHVN
BIOHAVEN LTDHealthcare$2.32B
0.64%
32SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.62%
33AGL
AGILON HEALTH INCHealthcare$2.17B
0.60%
34CDNA
CAREDX INCHealthcare$2.05B
0.57%
35SNDX
SYNDAX PHARMACEUTICALS INCHealthcare$2.02B
0.56%
36AMLX
AMYLYX PHARMACEUTICALS INCHealthcare$1.97B
0.55%
37DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
0.54%
38NVCR
NOVOCURE LTDHealthcare$1.84B
0.51%
39ZYME
ZYMEWORKS INCHealthcare$1.77B
0.49%
40BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.48%
41ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.47%
42FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.46%
43CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
0.46%
44VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.44%
45NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.44%
46INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.43%
47PRGO
PERRIGO CO PLCHealthcare$1.48B
0.41%
48MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.40%
49AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.38%
50XNCR
XENCOR INCHealthcare$1.30B
0.36%
51QDEL
QUIDELORTHO CORPHealthcare$1.19B
0.33%
52MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.32%
53EYPT
EYEPOINT INCHealthcare$1.12B
0.31%
54CGEM
CULLINAN THERAPEUTICS INCHealthcare$1.09B
0.30%
55PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.28%
56FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.28%
57VOR
VOR BIOPHARMA INCHealthcare$980M
0.27%
58KURA
KURA ONCOLOGY INCHealthcare$964M
0.27%
59ANNX
ANNEXON INCHealthcare$950M
0.26%
60TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.24%
61REPL
REPLIMUNE GROUP INCHealthcare$859M
0.24%
62CLYM
CLIMB BIO INCHealthcare$727M
0.20%
63AURA
AURA BIOSCIENCES INCHealthcare$723M
0.20%
64SPRY
ARS PHARMACEUTICALS INCHealthcare$695M
0.19%
65EVH
EVOLENT HEALTH INCHealthcare$654M
0.18%
66ACHV
ACHIEVE LIFE SCIENCES INCHealthcare$644M
0.18%
67NGNE
NEUROGENE INCHealthcare$590M
0.16%
68MYGN
MYRIAD GENETICS INCHealthcare$584M
0.16%
69ARVN
ARVINAS INCHealthcare$517M
0.14%
70CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.12%
71UPB
UPSTREAM BIO INCHealthcare$382M
0.11%
72ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.10%
73VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.09%
74LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.09%
75FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.08%
76TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.08%
77TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.07%
78SRZN
SURROZEN INCHealthcare$255M
0.07%
79RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.07%
80ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.07%
81GLSI
GREENWICH LIFESCIENCES INCHealthcare$240M
0.07%
82SMTI
SANARA MEDTECH INCHealthcare$229M
0.06%
83KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.06%
84IMUX
IMMUNIC INCHealthcare$207M
0.06%
85KRRO
KORRO BIO INCHealthcare$177M
0.05%
86RCEL
AVITA MEDICAL INCHealthcare$157M
0.04%
87PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.04%
88AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.04%
89SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.03%
90RLYB
RALLYBIO CORPHealthcare$87M
0.02%
91ACET
ADICET BIO INCHealthcare$76M
0.02%
92CLNN
CLENE INCHealthcare$76M
0.02%
93IMA
IMAGENEBIO INCHealthcare$61M
0.02%
94INKT
MINK THERAPEUTICS INCHealthcare$53M
0.01%
95TIL
INSTIL BIO INCHealthcare$50M
0.01%

Full long-leg book as of July 2026 · cap-weighted · total market cap $361.77B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
19%4
16%5
31%8
3%7
7%12
5%9
2%22
1%3
1%4

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 87% toward Large, 57% toward Growth. +16% unclassified (21 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt87% → Large
SmallLarge
Value ↔ growth tilt57% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.3 (95% CI 0.8-1.5)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
13.0%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.34x
within
parametric
1.22x
within
cornish fisher
1.11x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2004
Before publication (pre-2004)
0.29
Sharpe · 8.8% p.a.
January 1999December 2004 · 72 mo
Since publication
0.18
Sharpe · 2.9% p.a.
January 2005July 2026 · 259 mo
Change in Sharpe−0.10Sharpe weakened since publication67% of the prior annual return given up

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
77%
20 of 26 3-year windows made money
Worst window
-0.67
Sharpe, January 2023 – December 2025
January 1999July 2026
Median Sharpe
0.26
Dispersion
0.43
Best window
1.05

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.58.8%-13.7%
3 yearsp.a.13.1%-14.2%
5 yearsp.a.2.3%-2.3%
10 yearsp.a.10.9%1.0%
Since inceptionp.a.11.3%2.2%
Calendar years
YearLong legLong-short
20267 mo27.7%9.7%
202522.7%-27.1%
2024-7.3%-16.9%
20232.0%-0.1%
2022-26.8%8.2%
202132.4%52.8%
202036.9%3.4%
201917.5%-12.3%
20181.3%-0.7%
201731.6%11.7%
2016-6.7%6.1%
20159.7%-1.6%
201430.4%5.9%
201336.1%-11.0%
201226.1%7.6%
201111.0%8.9%
201012.2%6.9%
20093.7%-13.9%
2008-19.3%5.7%
2007-0.5%-11.9%
200621.8%30.7%
20057.5%-0.5%
2004-14.1%-14.8%
2003105.0%48.7%
2002-44.7%-15.3%
20013.3%16.7%
200063.8%6.2%
199921.5%-4.7%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FDNH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2022-06-05 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$361.77B

Methodology

The Foundry Healthcare dNOA Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a dNOA signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.